12
Participants
Start Date
October 1, 2021
Primary Completion Date
October 1, 2026
Study Completion Date
October 1, 2027
Adenovirus Specific T lymphocytes
ADV-VSTs is being proposed for the treatment of refractory ADV infection and/or disease in these populations using haploidentical donors for ease of donor selection, antiviral immunity, coupled with a high-throughput antigen stimulation/IFN-γ capture system (Miltenyi Biotec, CliniMACS Prodigy® System) for rapid and less costly isolation of ADV-VSTs.
RECRUITING
Nationwide Children's Hospital, Columbus
Nationwide Children's Hospital
OTHER